Skip to main content Skip to footer

Immune Effector Cell Therapies

Baylor Charles A. Sammons Cancer Center – Dallas

About immune effector cell therapy

Building on its extensive experience in stem cell transplantation, the program has served as a springboard for developing a comprehensive immune effector cell therapy program. CAR-T therapy, an approach that reengineers a patient’s immune cells to be able to recognize and attack cancer cells, is a new and important building block for the immune effector cell therapy program.

For the past 30 years, adoptive cellular therapy with immune effector cells including a variety of lymphocytes, have been developed at research centers around the world, including Baylor University Medical Center, part of Baylor Scott & White Health. Chimeric Antigen Receptor (CAR) T cells have emerged from the lab as FDA-approved treatments for a variety of cancers. This includes some gene-modified T cells and natural (NK) cells. The future for effector cell therapy is bright, as it becomes the treatment of choice for many cancer patients. Baylor Dallas will continue to play a leading role in these pioneering efforts. Read more about CAR-T Cell Therapy on our medical professional website.

{6}

Contact Us

Our patient navigators will work and coordinate with you to find the right oncology specialist

Advancing cancer care with personalized CAR-T

 
 

Baylor Charles A. Sammons Cancer Center – Dallas is the first center in North Texas to offer the first FDA approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (DLBCL), a type of non-Hodgkin’s lymphoma. CAR-T therapy allows a patient’s own immune system to help fight a disease. CAR-T clinical trials as well as other exciting immunotherapy applications are now available at Baylor Dallas. This important research has led to game-changing treatments that could improve the lives of cancer patients across Texas.

The treatment

 

CAR-T is a personalized therapy in which:

 
  • A patient’s own immune cells are removed from his or her body
  • Genetically reprogrammed
  • Infused back into the patient to seek and destroy cancer cells
Scroll To Top